US biotech Acorda Therapeutics is discontinuing development of its experimental Parkinson’s disease therapy tozadenant on concerns over patient safety. More: Acorda drops experimental Parkinson’s drug Source: News
read moreNHS England says it is planning to accelerate the NHS’ national research strategy, “cutting bureaucracy and speeding up access to new and innovative treatments”. More: NHS England consults on simplifying research processes Source: News
read moreThe European Medicines Agency has issued a marketing authorisation for Orexo and MundiPharma’s Zubsolv (buprenorphine and naloxone) for opioid dependence. More: EU nod for opioid dependence therapy Source: News
read moreEuropean regulators are allowing earlier use of Janssen’s Zytiga in the treatment pathway for metastatic prostate cancer. More: Janssen’s Zytiga approved for earlier use in prostate cancer Source: News
read moreAmsterdam has been named as the new home of the European Medicines Agency, triggering the start of an “ambitious” relocation programme that must be completed within 16 months. More: EMA move: “London’s loss is Amsterdam’s gain” Source: News
read morePfizer is in a tug of war with several states that intend to use some of its drugs to carry out executions. More: Pfizer in fight with states over their intent to use its drugs for executions Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals